The Gastritis Treatment Market size was valued at USD 5.26 Bn in 2024, and the total Gastritis Treatment Market revenue is growing at a CAGR of 4.5% from 2025 to 2032, reaching USD 7.99 Bn by 2032.Gastritis Treatment Market Overview
The gastritis treatment market encompasses a broad range of therapeutic solutions aimed at alleviating inflammation of the stomach lining caused by factors such as Helicobacter pylori (H. pylori) infection, prolonged use of NSAIDs, stress, and autoimmune conditions. This market includes prescription medications like proton pump inhibitors (PPIs), antacids, antibiotics, H2-receptor antagonists, and protective agents, offering an in-depth perspective on the available treatment classes. The report evaluates these therapeutic categories, providing clarity on their role in managing gastritis across diverse patient populations. The gastritis treatment market is influenced by several key growth drivers, including a rising prevalence of gastrointestinal disorders, an expanding geriatric population, and changing dietary habits shaped by the aggressive marketing strategies of the global food industry. Additionally, the report examines the market’s supply chain, highlighting the availability of active compounds and the role of the generic drug segment, particularly generic drug manufacturing in cost-effective regions, which supports affordability and accessibility for patients worldwide. From a regional perspective, the gastritis treatment market is dominated by North America in 2024, owing to its advanced healthcare infrastructure, higher diagnosis rates, and well-established surgical and diagnostic capabilities. Europe follows closely due to strong healthcare systems and increasing awareness. Meanwhile, the Asia-Pacific market is forecast to witness substantial growth, driven by a combination of rising healthcare access and increased global demand for gastritis treatments. The report also profiles major players shaping the competitive landscape, including Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, and Takeda Pharmaceutical Company Limited. Furthermore, the gastritis treatment market report outlined key opportunities and potential growth avenues beyond traditional hospital settings. This includes the role of retail pharmacies, chain drugstores, and online platforms as important end-user segments. By detailing market drivers and emerging trends, the report provides strategic insights into how industry stakeholders can capture market share within the broader gastric mucosal disease treatment ecosystem.To know about the Research Methodology :- Request Free Sample Report
Gastritis Treatment Market Dynamics
Rising Prevalence of Gastrointestinal Disorders to Drive Gastritis Treatment Market Growth The gastritis treatment market is primarily driven by the increasing global prevalence of gastrointestinal disorders, including gastritis, which affects millions annually due to factors such as poor dietary habits, stress, excessive alcohol consumption, and widespread use of NSAIDs. Additionally, the growing aging population is more susceptible to digestive issues, which further boosts the demand for effective treatment options. The report highlights that this rising disease burden has led to increased healthcare spending and greater adoption of advanced diagnostic and therapeutic solutions, significantly propelling market growth. Side Effects and Misdiagnosis Risks to Create Gastritis Treatment Market Restraints A key restraint in the gastritis treatment market is the potential side effects associated with long-term use of medications such as proton pump inhibitors (PPIs) and antibiotics, which can lead to issues like nutrient malabsorption or antibiotic resistance. Moreover, the similarity of gastritis symptoms with other gastrointestinal conditions often results in misdiagnosis or delayed treatment, hampering timely intervention. As highlighted in the report, these factors can limit patient adherence and pose challenges for healthcare providers, thereby restricting market expansion. Advancements in Personalized Medicine and Diagnostics to Create Gastritis Treatment Market Opportunity The gastritis treatment market presents significant growth opportunities through advancements in personalized medicine and diagnostic technologies. Innovations such as non-invasive testing, genetic profiling, and biomarker-based diagnostics enable more accurate detection and tailored treatment plans, improving patient outcomes. The report emphasizes that increased research investments and the integration of AI in gastroenterology offer potential for early diagnosis and targeted therapies, especially for chronic and H. pylori-induced gastritis, unlocking new avenues for market players.Global Gastritis Treatment Market Segment Analysis
Based on type, the acute gastritis segment dominated the Gastritis Treatment Market, with a market size of USD xx Bn in 2024 and is estimated to grow at a CAGR of xx% during 2025-2032. Acute Gastritis is caused by the overuse of NSAIDs (Non-Steroidal Anti-Inflammatory) drugs like sodium naproxen, ibuprofen, and diclofenac, with complications such as hemorrhages and erosion. It is analyzed by antacids like famotidine (Pepcid) and proton pump inhibitors that aid in the suppression of excessive acid production, assisting in the global market’s growth. The MMR report will provide an accurate prediction of the contribution of the various segments, like type, drug class, and end user, to the growth of the gastritis treatment market size.Global Gastritis Treatment Market Regional Insights
North America accounted for the largest market share in 2024, with a market value of US$ xx Mn; the regional market is expected to register a CAGR of xx% during 2024-2030. Fast food chains' broad presence in this region, as well as a developing sedentary lifestyle culture, which contributes to a growing gastritis patient pool and a growing geriatric population, are expected to boost the growth of the gastritis treatment market. Furthermore, increased alcohol abuse, as well as the presence of major key players, are expected to propel the market forward. According to a published poll, nearly one in every 100 people in the US suffers from gastritis. As a result, the market will develop faster during the anticipated period as the patient population grows. Furthermore, factors such as increased government initiatives and funding for research, advancements in advanced medical treatment choices, and the availability of beneficial reimbursement policies are expected to drive the expansion of the gastritis treatment market in the US. Europe occupied the second largest market share of xx% in 2024, thanks to the availability of advanced treatment facilities, recognised healthcare infrastructure, along the presence of a flourishing medical device market, which helps in efficient and accurate diagnosis. Furthermore, due to the increasing number of lactose-intolerant issues, vulnerability to falling prey to gastritis is more likely to lead to an increasing number of gastritis sufferers. Thus, fuelling the market growth during the forecast period. The objective of the report is to present a comprehensive analysis of the global Gastritis Treatment Market to the stakeholders in the industry. The past and current status of the industry, with the forecasted market size and trends, are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear, futuristic view of the industry to the decision-makers. The report also helps in understanding the global Gastritis Treatment Market dynamics, structure by analyzing the market segments and projects the global Gastritis Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Gastritis Treatment Market makes the report an investor’s guide.Gastritis Treatment Market Competitive Landscape
The competitive landscape of the Gastritis Treatment Market is dominated by two organizations, Pfizer Inc. and AstraZeneca plc. The stronghold of Pfizer in the market share of gastritis treatments is due to pharmacy availability of both prescription medications and OTC products in numerous formulations, including proton pump inhibitors, PPIs and antibiotics. With a strong, established distribution network in hospitals, pharmacies and e-commerce and ongoing research and development to improve drug effectiveness and bioavailability, they continue to expand their market share. Pfizer also continues to develop new formulations, through mergers and acquisitions, distribution or marketing intermediaries, and to seek ways of understanding product effectiveness. AstraZeneca has a well-known product, Nexium, that is one of the most common and potent prescription medications for gastritis, which is usually symptomatic of acid-related gastric disorders. Because they continue to innovate in next-generation phosphodiesterase delivery systems and also invest multi-million dollars in R&D in acid-suppressing therapies, they maintain a priority in the development of acid suppressors in the pharmacy chain. AstraZeneca also has an extensive pipeline of products in development on a routine basis, and frequently works with partners and in other corporate relationships to increase its reach in the market. These two companies together have strong advantages in the gastritis treatment market and they have a strong negotiating effect in driving treatment advancement and patient experience in the North American Gastritis market as they leverage their science, products, and strategic goals in the market.Gastritis Treatment Market Recent Developments:
1. Takeda Pharmaceutical (Japan) – March 2024 Received FDA approval for Vonoprazan (TAK-438) in the U.S., a potent acid-suppressing drug for erosive gastritis. 2. Pfizer (U.S.) – July 2024 Launched "Refametinib + Proton Pump Inhibitor (PPI)" combo therapy for H. pylori-resistant gastritis in Phase III trials. 3. RedHill Biopharma (Israel) – October 2024 Expanded access to Talicia (rifabutin-based therapy) in Europe for antibiotic-resistant H. pylori gastritis. 4. AstraZeneca (UK/Sweden) – January 2025 Announced "GastroShield", a mucosal protective drug targeting chronic atrophic gastritis, entering Phase IIb trials. 5. Daewoong Pharmaceutical (South Korea) – May 2025 Developed "Fexuprazan (DWP14012)", a new-generation PPI, approved in Asia for NSAID-induced gastritis.Gastritis Treatment Market Key Trends
1. Move Toward the Development of More Targeted and Personalized Therapies The FDA fast-tracking approval of biologic therapies, and the research and approval of new precision medicine signal a clear trend to deal with the root causes of gastritis, such as H.pylori-induced mucosal inflammation damage. Companies are heroically pivoting to patient-specific therapy development, rather than just being mired in symptom management, further suggesting a movement toward personalized care strategies in the field of gastroenterology. 2. Adoption of Artificial Intelligence and Advanced Research and Development Technologies The emergence of AI-based drug discovery platforms espouses the pharmaceutical industry’s adoption of artificial intelligence and machine learning to find new compounds, while expediting process timeframes. This exemplifies a larger transformative phase of drug research through digital adaptation and R&D methodology transformation, which increasingly shapes research, reduces costs, and enriches research-through-data.Gastritis Treatment Market Scope: Inquiry Before Buying
Gastritis Treatment Market Report Coverage Details Base Year: 2024 Forecast Period: 2025-2032 Historical Data: 2019 to 2024 Market Size in 2024: USD 5.26 Bn. Forecast Period 2025 to 2032 CAGR: 4.5% Market Size in 2032: USD 7.99 Bn. Segments Covered: by Drug Class Acid-blocking medicines Antibiotics Antacids Others by Type Acute Gastritis Chronic Gastritis Erosive Gastritis Non-Erosive Gastritis by End User Government Hospital Medical Practitioners Others Gastritis Treatment Market, by Region
North America (United States, Canada, and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, ASEAN, Indonesia, Philippines, Malaysia, Vietnam, Thailand, ASEAN, Rest of Asia Pacific) Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A) South America (Brazil, Argentina, Rest of South America)Gastritis Treatment Market: Key Players are
North America 1. Pfizer Inc. – USA 2. AbbVie Inc. – USA 3. Amgen Inc. – USA 4. Bristol-Myers Squibb – USA 5. Johnson & Johnson (Janssen Pharmaceuticals) – USA 6. Takeda Pharmaceuticals USA, Inc. – USA (subsidiary of Japan’s Takeda) Europe 1. GlaxoSmithKline plc (GSK) – United Kingdom 2. AstraZeneca plc – United Kingdom 3. Bayer AG – Germany 4. Sanofi S.A. – France 5. Novartis AG – Switzerland 6. Boehringer Ingelheim – Germany Asia-Pacific 1. Takeda Pharmaceutical Company Limited – Japan 2. Dr. Reddy’s Laboratories – India 3. Sun Pharmaceutical Industries Ltd. – India 4. Daiichi Sankyo Company, Limited – Japan 5. Cipla Ltd. – India 6. Aurobindo Pharma Ltd. – IndiaFrequently Asked Questions:
1) What was the market CAGR of the Global Gastritis Treatment Market during 2025-2032? Ans - Global Gastritis Treatment Market is expected to grow at a rate of 4.5% CAGR from 2025 to 2032. 2) What is the market segment of the Gastritis Treatment Market? Ans -The market segments are based on Drug Class, Type and End User. 3) What is the forecast period considered for the Global Gastritis Treatment Market? Ans -The forecast period for the Global Gastritis Treatment Market is 2025 to 2032. 4) What is the market size of the Global Gastritis Treatment Market in 2032? Ans – Global Gastritis Treatment Market is estimated as worth USD 7.99 Bn. by 2032 5) Which region is dominant in the Global Gastritis Treatment Market in 2024? Ans -In 2024, the North America region dominated the Global Gastritis Treatment Market.
1. Gastritis Treatment Market Introduction 1.1. Study Assumptions and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Gastritis Treatment Market: Competitive Landscape 2.1. Ecosystem Analysis 2.2. MMR Competition Matrix 2.3. Competitive Landscape 2.4. Key Players Benchmarking 2.4.1. Company Name 2.4.2. Business Segment 2.4.3. End-user Segment 2.4.4. Revenue (2024) 2.4.5. Company Locations 2.5. Market Structure 2.5.1. Market Leaders 2.5.2. Market Followers 2.5.3. Emerging Players 2.6. Mergers and Acquisitions Details 2.7. KANO Model Analysis 3. Global Gastritis Treatment Market: Antibiotics 3.1. Region-wise Trends of Gastritis Treatment Market 3.1.1. North America Gastritis Treatment Market Trends 3.1.2. Europe Gastritis Treatment Market Trends 3.1.3. Asia Pacific Gastritis Treatment Market Trends 3.1.4. Middle East and Africa Gastritis Treatment Market Trends 3.1.5. South America Gastritis Treatment Market Trends 3.2. Gastritis Treatment Market Antibiotics 3.2.1.1. Rising Advancement in Treatment 3.2.2. Global Gastritis Treatment Market Restraints 3.2.3. Global Gastritis Treatment Market Opportunities 3.2.3.1. Rising Demand For Gastritis Treatment 3.2.4. Global Gastritis Treatment Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Using Tree-Map Analysis 3.4.1. Political 3.4.2. Economical 3.4.3. Social 3.5. Regulatory Landscape by Region 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. Gastritis Treatment Market: Global Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 4.1. Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 4.1.1. Acute Gastritis 4.1.2. Chronic Gastritis 4.1.3. Erosive Gastritis 4.1.4. Non Erosive Gastritis 4.2. Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 4.2.1. Government 4.2.2. Hospitals 4.2.3. Medical Practitioners 4.2.4. Others 4.3. Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 4.3.1. Acid Blocking Medicines 4.3.2. Antibiotics 4.3.3. Antacids 4.3.4. Others 4.4. Gastritis Treatment Market Size and Forecast, by Region (2024-2032) 4.4.1. North America 4.4.2. Europe 4.4.3. Asia Pacific 4.4.4. Middle East and Africa 4.4.5. South America 5. North America Gastritis Treatment Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 5.1. North America Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 5.1.1. Acute Gastritis 5.1.2. Chronic Gastritis 5.1.3. Erosive Gastritis 5.1.4. Non Erosive Gastritis 5.2. North America Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 5.2.1. Hospitals & Diagnostic Centres 5.2.2. Hospitals 5.2.3. Medical Practitioners 5.2.4. Others 5.3. North America Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 5.3.1. Acid Blocking Medicines 5.3.2. Antibiotics 5.3.3. Antacids 5.3.4. Non Erosive Gastritis 5.4. North America Gastritis Treatment Market Size and Forecast, by Country (2024-2032) 5.4.1. United States 5.4.1.1. United States Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 5.4.1.1.1. Acute Gastritis 5.4.1.1.2. Chronic Gastritis 5.4.1.1.3. Erosive Gastritis 5.4.1.1.4. Non Erosive Gastritis 5.4.1.2. United States Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 5.4.1.2.1. Government 5.4.1.2.2. Hospitals 5.4.1.2.3. Medical Practitioners 5.4.1.2.4. Others 5.4.1.3. United States Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 5.4.1.3.1. Acid Blocking Medicines 5.4.1.3.2. Antibiotics 5.4.1.3.3. Antacids 5.4.1.3.4. Others 5.4.2. Canada 5.4.2.1. Canada Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 5.4.2.1.1. Acute Gastritis 5.4.2.1.2. Chronic Gastritis 5.4.2.1.3. Erosive Gastritis 5.4.2.1.4. Non Erosive Gastritis 5.4.2.2. Canada Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 5.4.2.2.1. Government 5.4.2.2.2. Hospitals 5.4.2.2.3. Medical Practitioners 5.4.2.2.4. Others 5.4.2.3. Canada Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 5.4.2.3.1. Acid Blocking Medicines 5.4.2.3.2. Antibiotics 5.4.2.3.3. Antacids 5.4.2.3.4. Others 5.4.3. Mexico 5.4.3.1. Mexico Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 5.4.3.1.1. Acute Gastritis 5.4.3.1.2. Chronic Gastritis 5.4.3.1.3. Erosive Gastritis 5.4.3.1.4. Non Erosive Gastritis 5.4.3.2. Mexico Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 5.4.3.2.1. Government 5.4.3.2.2. Hospitals 5.4.3.2.3. Medical Practitioners 5.4.3.2.4. Others 5.4.3.3. Mexico Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 5.4.3.3.1. Acid Blocking Medicines 5.4.3.3.2. Antibiotics 5.4.3.3.3. Antacids 5.4.3.3.4. Others 6. Europe Gastritis Treatment Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 6.1. Europe Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.2. Europe Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.3. Europe Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4. Europe Gastritis Treatment Market Size and Forecast, by Country (2024-2032) 6.4.1. United Kingdom 6.4.1.1. United Kingdom Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.1.2. United Kingdom Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.1.3. United Kingdom Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.2. France 6.4.2.1. France Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.2.2. France Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.2.3. France Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.3. Germany 6.4.3.1. Germany Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.3.2. Germany Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.3.3. Germany Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.4. Italy 6.4.4.1. Italy Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.4.2. Italy Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.4.3. Italy Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.5. Spain 6.4.5.1. Spain Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.5.2. Spain Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.5.3. Spain Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.6. Sweden 6.4.6.1. Sweden Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.6.2. Sweden Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.6.3. Sweden Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.7. Austria 6.4.7.1. Austria Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.7.2. Austria Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.7.3. Austria Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 6.4.8. Rest of Europe 6.4.8.1. Rest of Europe Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 6.4.8.2. Rest of Europe Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 6.4.8.3. Rest of Europe Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7. Asia Pacific Gastritis Treatment Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 7.1. Asia Pacific Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.2. Asia Pacific Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.3. Asia Pacific Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4. Asia Pacific Gastritis Treatment Market Size and Forecast, by Country (2024-2032) 7.4.1. China 7.4.1.1. China Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.1.2. China Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.1.3. China Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.2. S Korea 7.4.2.1. S Korea Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.2.2. S Korea Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.2.3. S Korea Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.3. Japan 7.4.3.1. Japan Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.3.2. Japan Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.3.3. Japan Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.4. India 7.4.4.1. India Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.4.2. India Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.4.3. India Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.5. Australia 7.4.5.1. Australia Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.5.2. Australia Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.5.3. Australia Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.6. Indonesia 7.4.6.1. Indonesia Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.6.2. Indonesia Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.6.3. Indonesia Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.7. Philippines 7.4.7.1. Philippines Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.7.2. Philippines Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.7.3. Philippines Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.8. Malaysia 7.4.8.1. Malaysia Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.8.2. Malaysia Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.8.3. Malaysia Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.9. Vietnam 7.4.9.1. Vietnam Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.9.2. Vietnam Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.9.3. Vietnam Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.10. Thailand 7.4.10.1. Thailand Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.10.2. Thailand Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.10.3. Thailand Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 7.4.11. Rest of Asia Pacific 7.4.11.1. Rest of Asia Pacific Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 7.4.11.2. Rest of Asia Pacific Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 7.4.11.3. Rest of Asia Pacific Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 8. Middle East and Africa Gastritis Treatment Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 8.1. Middle East and Africa Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 8.2. Middle East and Africa Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 8.3. Middle East and Africa Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 8.4. Middle East and Africa Gastritis Treatment Market Size and Forecast, by Country (2024-2032) 8.4.1. South Africa 8.4.1.1. South Africa Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 8.4.1.2. South Africa Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 8.4.1.3. South Africa Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 8.4.2. GCC 8.4.2.1. GCC Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 8.4.2.2. GCC Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 8.4.2.3. GCC Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 8.4.3. Nigeria 8.4.3.1. Nigeria Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 8.4.3.2. Nigeria Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 8.4.3.3. Nigeria Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 8.4.4. Rest of ME&A 8.4.4.1. Rest of ME&A Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 8.4.4.2. Rest of ME&A Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 8.4.4.3. Rest of ME&A Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 9. South America Gastritis Treatment Market Size and Forecast by Segmentation (by Value in USD Bn.) (2024-2032) 9.1. South America Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 9.2. South America Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 9.3. South America Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 9.4. South America Gastritis Treatment Market Size and Forecast, by Country (2024-2032) 9.4.1. Brazil 9.4.1.1. Brazil Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 9.4.1.2. Brazil Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 9.4.1.3. Brazil Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 9.4.2. Argentina 9.4.2.1. Argentina Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 9.4.2.2. Argentina Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 9.4.2.3. Argentina Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 9.4.3. Rest of South America 9.4.3.1. Rest of South America Gastritis Treatment Market Size and Forecast, By Type(2024-2032) 9.4.3.2. Rest of South America Gastritis Treatment Market Size and Forecast, By End User(2024-2032) 9.4.3.3. Rest of South America Gastritis Treatment Market Size and Forecast, By Drug Class(2024-2032) 10. Company Profile: Key Players (Detailed Profile for all Major Industry Players) 10.1. Pfizer Inc. – New York, United States 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Recent Developments 10.2. GlaxoSmithKline plc (GSK) – Brentford, United Kingdom 10.3. AstraZeneca plc – Cambridge, United Kingdom 10.4. Johnson & Johnson – New Brunswick, New Jersey, United States 10.5. Bayer AG – Leverkusen, Germany 10.6. Takeda Pharmaceutical Company Limited – Tokyo, Japan 10.7. Abbott Laboratories – Illinois, United States 10.8. Sanofi S.A. – Paris, France 10.9. Novartis AG – Basel, Switzerland 10.10. Eisai Co., Ltd. – Tokyo, Japan 10.11. Sun Pharmaceutical Industries Ltd. – Mumbai, India 10.12. Dr. Reddy’s Laboratories Ltd. – Hyderabad, India 10.13. Aurobindo Pharma Ltd. – Hyderabad, India 10.14. Cadila Healthcare (Zydus Lifesciences Ltd.) – Ahmedabad, India 10.15. Procter & Gamble Co. (P&G Health) – Cincinnati, Ohio, United States 11. Key Findings 12. Analyst Recommendations 13. Gastritis Treatment Market: Research Methodology
